Biotech entity
Every one of those 1 sits in a single category, fda-approval. Donald Trump is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Dr. Anna Durbin appears in 1 tracked Biotech story from August 13, 2026.
Last mentioned: Aug 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, fda-approval. Donald Trump is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Dr. Anna Durbin appears in 1 tracked Biotech story from August 13, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Anna Durbin. Shared-story counts are live from our verified record — not editorial picks.
Biopharma executives face a potential forced revival of discontinued single-antigen measles, mumps, and rubella vaccines, requiring new manufacturing lines and regulatory work. Analysts estimate tens of millions in upfront costs and years of development before any unbundled schedule could be supplied.
Source: troyrecord.com · greeleytribune.com
Dr. Anna Durbin is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
